CARDIOVASCULAR JOURNAL OF AFRICA • Volume 33, No 5, September/October 2022 AFRICA 241 24. Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 2006; 47(6): 927–946. 25. Liu G, Yin G, Tang J, Ma D, Ru J, Huang X. Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage. J Hum Hypertens 2014; 28(12): 711–715. 26. Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter MC, Paul SM, et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation 2003; 108(9): 1059–1063. 27. Stenvinkel P. Endothelial dysfunction and inflammation – is there a link? Nephrol Dialysis Transplant 2001; 16(10): 1968–1971. 28. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45(2): 198–202. 29. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107(3): 363–369. 30. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. J Intern Med 2004; 255(2): 247–256. 31. Liu X, Liu M, Tsilimingras D, Schiffrin EL. Racial disparities in cardiovascular risk factors among diagnosed hypertensive subjects. J Am Soc Hypertens 2011; 5(4): 239–248. 32. Liu X, Liu Y, Tsilimingras D, Campbell KM. Racial disparity in the associations of microalbuminuria and macroalbuminuria with odds of hypertension: results from the NHANES study in the United States. Int Scholarly Res Notices 2013; 2013. 33. Nojilana B, Bradshaw D, Pillay-van Wyk V, Msemburi W, Laubscher R, Somdyala NIM, et al. Emerging trends in non-communicable disease mortality in South Africa, 1997–2010. S Afr Med J 2016; 106(5): 477–484. 34. Alberts M, Dikotope SA, Choma SR, Masemola ML, Modjadji SE, Mashinya F, et al. Health and demographic surveillance system profile: the Dikgale health and demographic surveillance system. Int J Epidemiol 2015; 44(5): 1565–1571. 35. Maimela E, Alberts M, Modjadji SE, Choma SS, Dikotope SA, Ntuli TS, et al. The prevalence and determinants of chronic non-communicable disease risk factors amongst adults in the Dikgale health demographic and surveillance system (HDSS) site, Limpopo Province of South Africa. PLoS One 2016; 11(2): e0147926. 36. Modjadji P, Madiba S. Childhood undernutrition and its predictors in a rural health and demographic surveillance system site in South Africa. Int J Environ Res Public Health 2019; 16(17): 3021. 37. Modjadji P, Madiba S. The double burden of malnutrition in a rural health and demographic surveillance system site in South Africa: a study of primary schoolchildren and their mothers. BMC Public Health 2019; 19(1): 1087. 38. Mashinya F, Alberts M, Cook I, Ntuli S. Determinants of body mass index by gender in the Dikgale Health and Demographic Surveillance System site, South Africa. Global Health Action 2018; 11(suppl 2): 1537613. 39. Shisana OL, Rehle T, Simbayi L, Zuma K, Dhansay A, Reddy P, et al. & the SANHANES-1 Team, South African National Health and Nutrition Examination Survey (SANHANES-1). Cape Town: HSRC Press, 2013. 40. Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, et al. Assessment of kidney function in type 2 diabetes. Nephrology 2010; 15(s1): S146–S161. 41. World Health Organization. Waist circumference and waist–hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008. 2011. 42. Crowther NJ, Norris SA. The current waist circumference cut point used for the diagnosis of metabolic syndrome in sub-Saharan African women is not appropriate. PloS One 2012; 7(11): e48883. 43. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. 2001. 44. Yu S, Yang H, Guo X, Zhang X, Zheng L, Sun Y. Prevalence of dyslipidemia and associated factors among the hypertensive population from rural northeast China. BMC Public Health 2015; 15(1): 1152. 45. Njelekela MA, Mpembeni R, Muhihi A, Mligiliche NL, Spiegelman D, Hertzmark E, et al. Gender-related differences in the prevalence of cardiovascular disease risk factors and their correlates in urban Tanzania. BMC Cardiovasc Disord 2009; 9(1): 30. 46. Schutte R, Schutte AE, Huisman HW, Glyn MC, van Rooyen JM, Malan NT, et al. Arterial stiffness, ambulatory blood pressure and low-grade albuminuria in non-diabetic African and Caucasian men: the SABPA study. Hypertens Res 2011; 34(7): 862–868. 47. Hsu C-C, Chang H-Y, Huang M-C, Hwang S-J, Yang Y-C, Tai T-Y, et al. Association between insulin resistance and development of microalbuminuria in type 2 diabetes: A prospective cohort study. Diabetes Care 2011; 34: 982–987. 48. Chen F, Yang W, Weng J, Jia W, Ji L, Xiao J, et al. Albuminuria: prevalence, associated risk factors and relationship with cardiovascular disease. J Diabetes Invest 2014; 5(4): 464–471. 49. Kalk WJ, Raal FJ, Joffe BI. The prevalence and incidence of and risk factors for, micro-albuminuria among urban Africans with type 1 diabetes in South Africa: An inter-ethnic study. Int J Diabetes Mellitus 2010; 2(3): 148–153. 50. Ijei I, Bello-Manga H, Yusuf R, Sani B, Mamman A. Pattern of haemostatic parameters and their relationship with microalbuminuria among hypertensives in northern Nigeria. Ann Health Res 2019; 5(2): 203–215. 51. Habbal R, Sekhri AR, Volpe M, i-Search investigators. Prevalence of microalbuminuria in hypertensive patients and its associated cardiovascular risk in clinical cardiology: Moroccan results of the global i-SEARCH survey – a sub-analysis of a survey with 21,050 patients in 26 countries worldwide. Cardiovasc J Afr 2010; 21(4): 200–205. 52. Molefe-Baikai O, Molefi M, Cainelli F, Rwegerera G. The prevalence of microalbuminuria and associated factors among patients with type 2 diabetes mellitus in Botswana. Nigerian J Clin Prac 2018; 21(11): 1430–1437. 53. Yusuf S, Vaz M, Pais P. Tackling the challenge of cardiovascular disease burden in developing countries. Am Heart J 2004; 148(1): 1–4. 54. Adejumo OA, Okaka EI, Okwuonu CG, Iyawe IO, Odujoko OO. Serum C-reactive protein levels in pre-dialysis chronic kidney disease patients in southern Nigeria. Ghana Med J 2016; 50(1): 31–38. 55. Labreuche J, Deplanque D, Touboul P-J, Bruckert E, Amarenco P. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis. Atherosclerosis 2010; 212(1): 9–15. 56. Varbo A, Nordestgaard BG, Tybjærg‐Hansen A, Schnohr P, Jensen GB, Benn M. Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Ann Neurol 2011; 69(4): 628–634. 57. Jalal D, Chonchol M, Etgen T, Sander D. C-reactive protein as a predictor of cardiovascular events in elderly patients with chronic kidney disease. J Nephrol 2012; 25(5): 719. 58. Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis 2003; 45(5): 405–413. 59. Pedrinelli R, Dell’Omo G, Di Bello V, Pellegrini G, Pucci L, Del Prato S, et al. Low-grade inflammation and microalbuminuria in hypertension.
RkJQdWJsaXNoZXIy NDIzNzc=